Table 2 Summary of enoxaparin prophylaxis and AT III administration and the frequency of thrombotic events
ALL-BFM 2000 | ALL-BFM 2009 | ALL-BFM 2017 | Total population | |
|---|---|---|---|---|
Enoxaparin prophylaxis during L-asparaginase | ||||
Yes | 66/72 (91.7%) | 78/78 (100%) | 23/23 (100%) | 167/173 (96.5%) |
No | 6/72 (8.3%) | 0/78 (0%) | 0/23 (0%) | 6/173 (3.5%) |
ATIII substitution during enoxaparin prophylaxis | ||||
Yes | 48/72 (66.7%) | 56/78 (71.8%) | 18/23 (78.3%) | 122/173 (70.5%) |
< 10 years of age | 29/52 (55.8%) | 45/65 (69.2%) | 16/21 (76.2%) | 90/138 (65.2%) |
> 10 years of age | 19/20 (95%) | 11/13 (84.6%) | 2/2 (100%) | 32/35 (91.4%) |
No | 24/72 (33.3%) | 22/78 (28.2%) | 5/23 (21.7%) | 51/173 (29.5%) |
Number of ATIII administrations | ||||
0 times | 24/72 (33.3%) | 22/78 (28.2%) | 5/23 (21.7%) | 51/173 (29.5%) |
1 time | 16/72 (22.2%) | 13/78 (16.7%) | 3/23 (13.0%) | 32/173 (18.5%) |
2 times | 9/72 (12.5%) | 14/78 (18.0%) | 5/23 (21.7%) | 28/173 (16.2%) |
3 times | 8/72 (11.1%) | 14/78 (18.0%) | 5/23 (21.7%) | 27/173 (15.6%) |
4 or more times (max. 9 times) | 15/72 (20.8%) | 15/78 (19.2%) | 5/23 (21.7%) | 35/173 (20.2%) |
Blockade of central venous catheter during induction | 7/72 (9.7%) | 4/78 (5.1%) | 3/23 (13.0%) | 14/173 (8.1%) |
Deep vein thrombosis | ||||
Yes | 3/72 (4.2%) | 1/78 (1.3%) | 1/23 (4.3%) | 5/173 (2.9%) |
No | 69/72 (95.8%) | 77/78 (98.7%) | 22/23 (95.7%) | 168/173 (97.1%) |